Mar. 18 at 2:12 PM
$CRNX filled gap from September, a high-upside rare‑disease biotech with a de‑risked lead asset and a deep pipeline behind it. The core bull case rests on PALSONIFY (paltusotine), the first once‑daily oral therapy for acromegaly, which now has FDA approval and is ramping as patients switch from painful long‑acting injectables to a more convenient pill. That launch creates a durable, specialty revenue base that can help fund a portfolio of oral drugs targeting congenital adrenal hyperplasia, Cushing’s disease, and other endocrine disorders where there are few effective options and pricing power is strong
